Summary
Biological psychiatry is the tradition within medicine that locates the causes of mental illness in the brain — in its anatomy, chemistry, and inherited structure — and pursues treatment through physical rather than purely psychological means. The tradition has two distinct historical phases. The first, centered in German university clinics between roughly 1860 and 1900, sought to map mental illness onto brain structures through microscopy and anatomy; it reached a dead end when anatomical research outran clinical usefulness. The second emerged after the 1950s, driven by psychopharmacology and genetics, and displaced psychoanalysis as the dominant framework of Western psychiatry. Historians differ sharply on how to read this arc: Edward Shorter treats it as genuine scientific progress; Roy Porter sees it as one pole of an unresolved tension that has driven psychiatry from its founding. Andrew Scull, writing in 2015, offers a colder verdict: despite the accumulation of DSM editions and decades of biological research, the aetiology of most serious mental illness remains obscure, its treatments are largely symptomatic and of dubious efficacy, and those who suffer from serious psychoses constitute one of the few segments of modern populations whose life expectancy has declined over the preceding quarter-century.(Andrew Scull, 2015)
Historical Origins
The intellectual lineage of biological psychiatry begins with the claim that mental illness is brain disease. In the mid-nineteenth century this was not yet a professional consensus but a polemical position, and the person most responsible for giving it institutional form was Wilhelm Griesinger, a German physician who established psychiatry at Berlin’s Charité hospital in 1865. Griesinger’s declaration — “patients with so-called mental illnesses are really individuals with illnesses of the nerves and brain” — was simultaneously a statement about aetiology, a claim about how psychiatry should be practiced, and an argument for integrating psychiatry into general medicine rather than leaving it as a closed guild of asylum keepers (Shorter, 1997). His 1861 revised textbook, arguing that mental illness was brain disease, became perhaps the most widely read psychiatric textbook in the Western world until Emil Kraepelin’s major work in the 1890s (Shorter, 1997). The Germans differed from the rest of the Western world in having, alongside their barracks-asylums, smaller clinics attached to universities where intensive research could proceed, a structural advantage that Griesinger’s appointment inaugurated and that would sustain German psychiatric science for the next seven decades.(Andrew Scull, 2015)
In 1822, Antoine-Laurent Bayle, working as an assistant physician at Charenton, conducted autopsies on some 200 corpses of mental patients.(Andrew Scull, 2015) He identified a cluster of symptoms he named paralysie générale (impairments of speech, loss of motor control, progressive sensory loss, and dramatic psychiatric deterioration ending in death) and found characteristic brain lesions in several cases.(Andrew Scull, 2015) This discovery was a significant empirical finding that reinforced the view that mental illness was rooted in the brain.(Andrew Scull, 2015) By the end of the nineteenth century, general paralysis of the insane accounted for twenty percent or more of male asylum admissions across Europe and North America.(Andrew Scull, 2015) The successful treatment of tertiary syphilis, which accounted for perhaps twenty percent of male admissions in the early twentieth century, is cited as one of the few genuine triumphs of the medicalization of madness.(Andrew Scull, 2015)
Dowbiggin’s Inheriting Madness (1991) fills in the French side of this story in greater detail. The 1819 and 1822 discoveries of brain membrane lesions in the paralytic insane by Antoine-Laurent Bayle and Louis Calmeil had inspired great enthusiasm among Parisian doctors who believed that further pathoanatomical research would reveal the brain lesions underlying other psychological disturbances — melancholy, mania, dementia. By the mid-1830s, however, that optimism had faded as no further lesions were found.(Ian Dowbiggin, 1991) What followed was not a retreat from somaticism but a strategic doubling down on it: Dowbiggin argues that French alienists needed insanity to be a somatic disease in order to legitimately exclude the Catholic clergy from diagnosis and treatment, since failure to demonstrate somatic pathology meant that priests and nuns retained de facto equal standing in managing the insane.(Ian Dowbiggin, 1991) The French Law of 1838 had granted alienists authority over public asylums, but it simultaneously exposed their therapeutic inadequacy, placing pressure on them to demonstrate superior knowledge or risk losing privileges to the Church.(Ian Dowbiggin, 1991) This professional logic — not simply scientific curiosity — explains why French alienists invested so heavily in somatic theories of mental illness through the middle decades of the century, and why, when anatomical research failed to deliver, they turned to hereditarian frameworks that could reconcile somatic disease models with their limited therapeutic results.(Ian Dowbiggin, 1991)
The institutional structure that allowed Germany to build on this template was its network of competing state universities, each nurturing research and postdoctoral publication through the habilitation system. No other country in the nineteenth century yoked researchers to publication at the same scale, and this structure guaranteed German scientific preeminence in psychiatry until the catastrophe of 1933 (Shorter, 1997).
The First Biological Psychiatry (c. 1860–1900)
What distinguishes the first biological psychiatry from earlier humoral accounts of mental disturbance was not simply the belief that mental illness had a physical basis — physicians had believed that since antiquity — but the commitment to finding that basis through systematic laboratory research (Shorter, 1997). The tools were the microscope, comparative neuroanatomy, and the accumulating techniques of experimental physiology.
The Scottish alienist W. A. F. Browne articulated in 1837 the professional logic that brain localization served: “The brain is at fault and not the mind.”(Andrew Scull, 2015) Framing insanity as a disease of the brain rather than the understanding protected religious sensibilities by locating pathology in a material organ.(Andrew Scull, 2015) Phrenology, developed by Gall and Spurzheim, gave this framing a working theoretical scaffold: if insanity was a physical disorder of specific brain organs, it was unambiguously a medical matter, and Spurzheim’s modifications supplied an explanation for why moral treatment could affect the disease course: by exercising and strengthening dormant or underdeveloped brain parts.(Andrew Scull, 2015) Phrenology thus reconciled brain-disease claims with the therapeutic successes asylum physicians actually observed.(Andrew Scull, 2015)
In Vienna, Theodor Meynert had by 1868 begun mapping the microscopic architecture of the brain and calling for a fundamental reorientation of psychiatry away from symptom labeling and toward understanding anatomical origins — quite independently of Griesinger’s parallel program in Berlin (Shorter, 1997). In the subsequent decades, as Shorter describes it, “an absolute craze for studying psychiatry with the microscope took possession of the German, Austrian, and Swiss universities” (Shorter, 1997). Paul Flechsig and Eduard Hitzig were among the celebrated scientists produced by this movement. Carl Wernicke’s 1874 demonstration that damage to a specific posterior brain region abolished the ability to understand spoken language represented, for Shorter, the high-water mark of the localization approach — and also, as Karl Jaspers later put it, the endpoint of what could be called “brain mythology” (Shorter, 1997).
Silas Weir Mitchell’s rest cure was a widely used mid-nineteenth-century treatment for nervousness (Shorter, 1997). It enforced bed rest, isolation from family, massage, high-calorie diet, and electrotherapy (Shorter, 1997). The cure functioned as an early form of psychotherapy through doctor-patient suggestion (Shorter, 1997).
As the microscopic research program accumulated findings without generating treatments, a parallel theoretical development reshaped the professional understanding of mental illness. In 1857, Bénédict-Augustin Morel published his Treatise on the Intellectual, Moral, and Physical Degeneracy of the Human Race, proposing that madness was the product of hereditary biological decay transmitted across generations.(Andrew Scull, 2015) Within a decade or a decade and a half, Morel’s ideas had become received wisdom. The mentally ill were no longer framed as victims of civilization’s stresses but as its antithesis: biologically inferior individuals whose deficiency was, in many cases, written on their physiognomy. Degeneration theory had evident ideological utility for the profession: it explained why the therapeutic optimism of asylum founders had not materialized, attributing the failure not to professional incompetence but to the inherent nature of mental illness itself, and it provided a new justification for permanent asylum segregation.(Andrew Scull, 2015)
In 1906, Alois Alzheimer identified the plaques and neurofibrillary tangles associated with the form of dementia that now bears his name.(Andrew Scull, 2015) In 1913, Hideyo Noguchi and J. W. Moore definitively demonstrated what had been suspected for two decades: that General Paralysis of the Insane was a tertiary stage of syphilis, identifying syphilitic spirochetes in the brains of paretics and removing all reasonable doubt.(Andrew Scull, 2015)
The figure who ended the first biological psychiatry and opened the second phase was Emil Kraepelin, a German psychiatrist who argued that the course of illness over time, not the symptom picture at any given moment, was the sharpest indicator of what disease a patient had. Kraepelin’s longitudinal approach — tracking patients across their entire illness careers and classifying by outcome — was the historic opponent of Wernicke’s cross-sectional, localizationist method. When Kraepelin’s framework won the professional argument, in the 1890s and after, it marked both the collapse of the first biological psychiatry and the emergence of the diagnostic tradition that still underlies modern classification (Shorter, 1997). Porter’s account largely agrees on Kraepelin’s significance: his nosological system, which combined earlier descriptions by Karl Kahlbaum (catatonia), Morel (démence précoce), and Ewald Hecker (hebephrenia) into the category of dementia praecox, became the forerunner of the modern concept of schizophrenia and the template for today’s DSM (Porter, 1997).
The Widening of Nervous Disease
Parallel to the laboratory program in German university clinics, a different expansion of biological psychiatry’s scope was underway in the clinic and the consulting room. George M. Beard, an American neurologist, coined the diagnosis of “neurasthenia” (weakness of the nerves) and proclaimed himself one of its victims. Beard insisted that “nervousness is a physical not a mental state” whose phenomena did not arise from emotional excess but from somatic depletion of nerve force.(Andrew Scull, 2015) The diagnosis created a lucrative office-based practice treating the exhausted professional classes while keeping the brain-disease framing intact for conditions that stopped well short of asylum-level severity.
Jean-Martin Charcot, working at the Salpêtrière in Paris, extended the biological program into the contested territory of hysteria. From the outset and throughout his career, Charcot maintained that hysteria was a real neurological disorder, rooted in as-yet-undiscovered lesions in the brain and nervous system, a position he held even as his own clinical observations showed that some hysterical paralyses followed pathways directly at odds with established neuroanatomy, reflecting lay misconceptions about how the body was structured rather than any organic lesion.(Andrew Scull, 2015) His death in 1893 triggered a rapid disavowal: even close collaborators dismissed his demonstrations as staged, and the search for the organic basis of hysteria effectively ended.
The Interwar Period: Physical Therapies and Therapeutic Nihilism
By the early twentieth century, the asylum system was in crisis (Porter, 1997). Porter notes that by 1900, the therapeutic optimism with which the nineteenth century had opened had almost entirely collapsed; asylums filled with incurable patients, and a German asylum physician in 1910 summarized the situation as “we know a lot and can do little” (Porter, 1997).
Julius Wagner-Jauregg developed malaria therapy for general paralysis of the insane in 1917, encountering an Italian prisoner with tertian malaria in the closing months of the war, drawing blood to infect patients and induce high fevers; the treatment was adopted internationally and won the 1927 Nobel Prize, the first awarded for a psychiatric intervention.(Andrew Scull, 2015) Hans Luxenburger’s 1928 large-scale twin survey provided the first solid evidence that a major psychiatric illness had an organic substrate.(Shorter, 1997)
The hope that focal infection caused all mental illness generated one of the most catastrophic therapeutic experiments of the era. Henry Cotton, superintendent of Trenton State Hospital in New Jersey, became convinced that chronic bacterial infections lurking in teeth, tonsils, colons, and other organs created toxins that poisoned the brain, and he began removing suspect tissue on a massive scale. Adolf Meyer, America’s most powerful psychiatrist and Cotton’s own mentor, was assigned to supervise an independent review of the outcomes; he discovered that the real mortality rate from Cotton’s surgeries approached 45 percent. Meyer suppressed the findings rather than trigger a scandal, allowing the operations to continue.(Andrew Scull, 2015)
Manfred Sakel developed insulin coma therapy in Vienna in 1933 after being assigned to a ward for schizophrenics, and he was soon claiming a seventy percent remission rate. By 1937, the treatment had been adopted in twenty-two countries. Between two and five percent of those treated died. Controlled trials eventually demonstrated that insulin coma therapy was without therapeutic value.(Andrew Scull, 2015) Ugo Cerletti and Lucio Bini developed electroconvulsive therapy (ECT) in Rome in 1938 after a chance visit to a slaughterhouse where pigs were stunned with electrical current before slaughter. ECT proved cheaper and more reliable than metrazol convulsion therapy and was quickly adopted internationally.(Andrew Scull, 2015)
Prefrontal lobotomy was developed by the Portuguese neurologist Egas Moniz, who could not operate himself due to arthritic hands and relied on Pedro Almeida Lima to perform the procedures.(Andrew Scull, 2015) The first operations began in November 1935, initially by boring holes in the skull and injecting alcohol into the frontal lobes.(Andrew Scull, 2015) When Moniz received the Nobel Prize in 1949, the number of lobotomies increased dramatically: by 1953 twenty thousand additional Americans had been lobotomized.(Andrew Scull, 2015) Walter Freeman developed the transorbital lobotomy, performing the operation through the eye socket with an ice pick in twenty minutes, using a mallet to break through the bone.(Andrew Scull, 2015) He demonstrated this technique in mass operations across American state hospitals, personally performing 2,400 such operations by 1957.(Andrew Scull, 2015)
Nineteenth-century practitioners felt persistent pressure to tell patients what they wanted to hear about the cause and nature of their illnesses.(Shorter, 1997) The electrotherapy used routinely on such patients in private practice was an empirically weak but ritually powerful intervention that relied largely on suggestion and the placebo effects of physician attention.(Shorter, 1997)
Scull’s summary judgment on this entire wave of interventions is that the driving forces were psychiatry’s crisis of legitimacy relative to germ-theory medicine, the desperation of patients’ families, fiscal pressure on state institutions, and the captive, rightless status of mental patients who had been morally and physically removed from the ranks of humankind and were presumed, by virtue of their mental state, to lack the capacity to make informed choices, with no countervailing forces to hold experimentation in check.(Andrew Scull, 2015)
The Second Biological Psychiatry: Psychopharmacology and the Displacement of Psychoanalysis
The decisive transformation came with psychopharmacology. Shorter’s central argument is that between the 1950s and the 1990s, a shift of professional authority occurred that displaced psychoanalysis and returned psychiatry to its brain-based orientation (Shorter, 1997). That shift had deep roots: the second biological psychiatry burst into clinical practice in the 1970s but had germinated decades earlier in Emil Kraepelin’s German Research Institute for Psychiatry (founded 1917), which nurtured the genetic research establishing brain-based etiologies for major psychiatric illness.(Shorter, 1997) Chlorpromazine, the first of the phenothiazines, was synthesized on 11 December 1950 by the French pharmaceutical house Rhône-Poulenc; Henri Laborit first recognized its psychiatric potential, and Pierre Deniker and Jean Delay introduced it at the Salpêtrière.(Andrew Scull, 2015) Smith, Kline & French secured FDA approval in 1954, and on an initial research investment of $350,000, the company’s net sales grew from $53 million in 1953 to $347 million by 1970, a large fraction of which was directly attributable to this single drug.(Andrew Scull, 2015) The drugs that drove the broader shift (lithium for mania, phenothiazines for psychosis, imipramine for depression) did not simply add tools; they implied a particular account of mental illness, namely that disorders of mood and thought reflected disturbances of brain chemistry amenable to pharmacological correction (Shorter, 1997)(Porter, 1997). John Cade’s 1948 discovery that lithium calmed manic patients, published in a small Australian journal and initially ignored, eventually became one of the most significant contributions in the history of psychopharmacology.(Shorter, 1997)
The professional consolidation of the second biological psychiatry required a diagnostic infrastructure to match its pharmacological ambitions. DSM-III, published in 1980, was the result. The task force was led by Robert Spitzer at Columbia University and dominated by biologically oriented psychiatrists, most of them drawn from Washington University in St. Louis. Unable to demonstrate convincing chains of causation for any major mental disorder, the task force abandoned the attempt and concentrated instead on maximizing inter-rater reliability: explicit symptom checklists that two clinicians applying the same criteria would apply consistently. Questions of validity (whether the classificatory system corresponded to aetiologically meaningful distinctions) were set to one side.(Andrew Scull, 2015) Psychoanalytic categories including “neurosis” were eliminated, and the resulting system, once insurance reimbursement made it obligatory for all American mental health professionals, became the de facto global standard.
The first-generation antipsychotics carried a serious iatrogenic burden. Long-term treatment with the phenothiazines produced tardive dyskinesia (sucking and smacking movements of the lips, rocking and uncontrolled movements of the extremities) in estimates ranging from fifteen to sixty percent of patients on extended regimens, a condition that was in most cases difficult to reverse and that was often mistaken by observers for signs of mental disturbance itself.(Andrew Scull, 2015) The second-generation “atypical” antipsychotics, marketed from the 1990s as both more effective and more tolerable, were later found by a Lancet editorial to be no more efficacious and no more distinct in side-effect profile than first-generation drugs.(Andrew Scull, 2015)
The Chemical Imbalance Theory: Whitaker’s Critique
The investigative journalist Robert Whitaker, in his 2010 Anatomy of an Epidemic, assembled a sustained critique of the chemical imbalance theory that constituted the second biological psychiatry’s public rationale. Whitaker is not a clinical researcher and his interpretations are contested by mainstream psychiatry; his evidence is documented here as a challenge grounded in published scientific literature rather than as authoritative finding.
Whitaker documents that the relabeling of psychiatric drugs from “tranquilizers” to “antidepressants,” “mood normalizers,” and “antipsychotics” occurred before any disease-specific mechanism was identified: by the late 1950s, pharmaceutical marketers had completed a linguistic transformation that implied disease-specific action where only sedating or stimulating effects had been demonstrated.(Whitaker, Robert, 2010) Smith Kline and French tested Thorazine on fewer than 150 psychiatric patients before submitting its FDA application in 1954, yet the company president publicly claimed it had undergone “the most rigorous testing imaginable.”(Whitaker, Robert, 2010) A 1963 NIMH trial showing neuroleptics more effective than placebo at reducing psychotic symptoms prompted researchers to rebrand them as disease-specific “antipsychotics,” completing the transformation.(Whitaker, Robert, 2010)
The serotonin/catecholamine hypothesis of depression arose from drug observations rather than disease pathology. Whitaker traces it to Bernard Brodie’s 1955 observation that reserpine depleted serotonin and made rabbits lethargic, while iproniazid and imipramine blocked this depletion — an inference from drug mechanisms rather than identified brain chemistry.(Whitaker, Robert, 2010) Joseph Schildkraut’s 1965 “catecholamine hypothesis” — the first formal pillar of biological psychiatry — was acknowledged by its own author as “at best a reductionistic oversimplification of a very complex biological state.”(Whitaker, Robert, 2010) The dopamine hypothesis of schizophrenia was constructed by combining Parkinson’s research showing dopamine deficiency in basal ganglia with the finding that antipsychotics blocked dopamine and amphetamines elevated it — an indirect inference, not direct measurement of schizophrenic brains.(Whitaker, Robert, 2010)
Whitaker frames the resulting situation as a choice between two historical narratives. By 1970, two competing histories were possible: either psychiatry had discovered drugs that corrected chemical imbalances in mentally ill brains, or it had turned drugs that perturb normal brain function into “magic bullets” to gain medical legitimacy.(Whitaker, Robert, 2010) The chemical imbalance theory reduced the brain’s near-infinite complexity — 100 billion neurons, 150 trillion synapses — to a simple disease mechanism: depression from low serotonin, schizophrenia from overactive dopamine pathways.(Whitaker, Robert, 2010)
The dopamine hypothesis of schizophrenia did not survive empirical testing. Multiple independent studies from 1975 onward found normal dopamine metabolite levels in the cerebrospinal fluid of unmedicated schizophrenic patients — contradicting the dopamine-excess hypothesis.(Whitaker, Robert, 2010) Elevated D2 receptor density found in schizophrenic brains at autopsy (Seeman 1978) was shown to be iatrogenic — caused by long-term neuroleptic use, not the disease itself — confirmed by both animal experiments and autopsy studies of drug-free patients.(Whitaker, Robert, 2010) By 1990, the dopamine hypothesis of schizophrenia was rejected by its own founders and leading researchers, yet the public continued to be told that antipsychotics worked like “insulin for diabetes.”(Whitaker, Robert, 2010)
Whitaker identifies the storytelling formula pharmaceutical companies used: identify a drug’s mechanism of action (raising or lowering a neurotransmitter) and then tell the public that the treated disease was caused by the opposite deficiency or excess — a circular logic that originated with ADHD and Ritalin and spread to depression and schizophrenia.(Whitaker, Robert, 2010) By 1998–2005, multiple independent scientists and textbooks explicitly stated that evidence for any biochemical theory of mental illness had never been found, including U.S. Surgeon General David Satcher admitting the “precise causes of mental disorders are not known.”(Whitaker, Robert, 2010) The chemical-imbalance theory persisted not because of evidence but because it allowed psychiatry to adopt a medical model — giving psychiatrists “anti-disease” pills comparable to antibiotics — fulfilling a long-held aspiration to be “real doctors.”(Whitaker, Robert, 2010)
NIMH director Steve Hyman’s 1996 paper “Initiation and Adaptation” established that all psychotropic drugs create “perturbations in neurotransmitter functions” that trigger compensatory brain adaptations, and after chronic administration produce “substantial and long-lasting alterations in neural function” leaving the brain in a “qualitatively as well as quantitatively different” state from normal.(Whitaker, Robert, 2010) On Whitaker’s reading, this means that prior to psychiatric drug treatment, patients diagnosed with schizophrenia, depression, and other disorders do not suffer from any known “chemical imbalance” — it is the medication that creates abnormal brain function.(Whitaker, Robert, 2010) He argues that the psychopharmacology revolution’s initial characterization of psychiatric drugs — as compounds perturbing normal brain function — was the scientifically accurate one; the later reconception as “magic bullets” correcting chemical imbalances was driven by wishful thinking and was not validated by research.(Whitaker, Robert, 2010)
The Commercial Infrastructure of the Second Biological Psychiatry
Whitaker’s account of the second biological psychiatry’s rise begins with a professional crisis. By the 1970s, medical school graduates choosing psychiatry had dropped from 11 percent to under 4 percent of the total. By 1975, nonphysician therapists — psychologists, social workers, counselors — outnumbered psychiatrists.(Whitaker, Robert, 2010) Three entrenched factions within the field (Freudian, biological, and social-community psychiatrists) prevented unified professional advocacy and left psychiatry exposed to the antipsychiatry critique in a way more unified disciplines could have resisted.(Whitaker, Robert, 2010) This institutional vulnerability shaped the urgency with which biological psychiatry pursued a narrative that would restore its medical legitimacy.
The APA’s response was deliberate and institutional. In 1981, the APA established a “division of publications and marketing” with an explicit mandate to “deepen the medical identification of psychiatrists” — functioning, as Whitaker characterizes it, as a marketing machine directed at the profession’s own members and the broader public.(Whitaker, Robert, 2010) The cultural moment was receptive: in 1984, journalist Jon Franklin won the Pulitzer Prize for reporting that psychiatry was “on the threshold of becoming an exact science,” based on the field’s “rapidly identifying molecules underlying human thought.”(Whitaker, Robert, 2010) Nancy Andreasen’s Broken Brain (1984), widely heralded as documenting a biological revolution, in fact confessed in its pages that the biological underpinnings of major psychiatric illness had not yet been identified. Twenty-five years later, they still had not been.(Whitaker, Robert, 2010)
Whitaker also documents the commercial infrastructure that sustained the second biological psychiatry. U.S. psychiatric drug sales grew from $503 million in 1985 to $24.2 billion in 2008 for antidepressants and antipsychotics alone; by 2008 one in eight Americans was taking a psychiatric drug.(Whitaker, Robert, 2010) Eli Lilly’s market capitalization grew from $10 billion in 1987 to $90 billion in 2000, a ninefold increase driven primarily by Prozac; this wealth flowed into academic medicine through key opinion leader (KOL) payments that aligned psychiatry with pharmaceutical interests.(Whitaker, Robert, 2010) Charles Nemeroff received at least $2.8 million from pharmaceutical companies between 2000 and 2007 while serving as a grant reviewer at the NIH; Frederick Goodwin received $1.2 million; and Joseph Biederman received at least $1.6 million while simultaneously conducting research that expanded pediatric bipolar diagnoses and drug use.(Whitaker, Robert, 2010) Johnson & Johnson created the Johnson & Johnson Center for Pediatric Psychopathology at Massachusetts General Hospital, run by Biederman, with an explicit stated goal to “move forward the commercial goals of J&J” — a document disclosed in a Senate investigation.(Whitaker, Robert, 2010) In 1980 the APA changed policy to allow pharmaceutical companies to sponsor “scientific” symposiums at annual meetings for a fee; the APA’s revenues jumped from $10.5 million in 1980 to $21.4 million in 1987, fueled by pharmaceutical industry funding.(Whitaker, Robert, 2010) The NIMH, the APA, and NAMI formed a coalition promoting the biological model, with pharmaceutical firms giving NAMI $11.72 million from 1996 to 1999.(Whitaker, Robert, 2010) The commercial interests created institutional incentives to promote the chemical imbalance narrative, market new drugs, and discourage investigation of negative long-term outcomes.(Whitaker, Robert, 2010) An internal NAMI document from the 1990s made the goal explicit: to “grow the market” for psychiatric medications, using patient-advocacy positioning and the moral authority of a grassroots organization to advance biological psychiatry’s commercial agenda.(Whitaker, Robert, 2010)
One visible consequence of this infrastructure was diagnostic expansion. After 1996, when the hypomania duration requirement for bipolar II was shortened from 4 days to 2 days, adult bipolar diagnoses rose 56 percent by 2004; prevalence estimates for bipolar spectrum conditions ranged from 6.4 percent (Judd’s “soft” bipolar count) to claims that as many as 1 in 4 adults qualified.(Whitaker, Robert, 2010) This expansion directly served the commercial interests of pharmaceutical companies marketing atypical antipsychotics and mood stabilizers as bipolar treatments, while also creating a feedback loop between loosening diagnostic criteria and expanding prescribing markets.
Shorter presents the broader shift as an unambiguous scientific success: the biological approach has demonstrated that mental illness is genetically influenced and neurochemically grounded, and its treatments have reduced suffering at a scale that psychoanalytic methods never achieved (Shorter, 1997). He is explicit that he is arguing against the academic historians of psychiatry — particularly those influenced by Michel Foucault — who have treated psychiatric institutions as instruments of social control and mental illness as a social construct (Shorter, 1997). His counter-argument is that mental illness has a biological reality independent of gender and class conventions, comparable to Parkinsonism or multiple sclerosis, even while he acknowledges that the experience of illness is shaped by culture (Shorter, 1997).
Porter notes that psychopharmacology brought new therapeutic optimism and cost-effectiveness, reducing the need for lengthy hospitalization (Porter, 1997). His conclusion is that as the twentieth century ended, “psychiatry lacks unity and remains hostage to the mind-body problem, buffeted back and forth between psychological and physical definitions of its object and its techniques” (Porter, 1997).
Historiographical Disputes
The two principal sources for this page hold incompatible positions on what biological psychiatry’s history means, and that disagreement is itself historically significant.
Shorter’s A History of Psychiatry (1997) is written explicitly as a counter to what he calls revisionist historiography — the tradition associated with Foucault, Andrew Scull, and others that reads the asylum and the psychiatric profession as instruments of capitalist or patriarchal social control [sho97-ch01-004; sho97-ch01-007]. Shorter argues that these accounts, while they have achieved cultural prestige, are factually incorrect: mental illness is biologically real, the therapeutic asylum represented genuine humanitarian progress over pre-institutional conditions, and the drug revolution of the 1950s represents the most successful outcome in psychiatry’s history. His narrative is explicitly teleological — from first biological psychiatry through psychoanalytic interlude to second biological psychiatry — and he does not treat this arc as triumphalist but as a corrective to historiographical distortion (Shorter, 1997).
Porter’s The Greatest Benefit to Mankind (1997), by contrast, presents the history of psychiatry as characterized by persistent irresolution (Porter, 1997). Porter notes that even Griesinger, the founding figure of biological psychiatry, conceded that not all pathological states were accompanied by detectable cerebral lesions, complicating any simple equation of mental illness with brain lesion (Porter, 1997).
Both accounts are products of 1997, written before the full consolidation of the DSM system, the neuroscience revolution, and the subsequent critiques of pharmaceutical industry influence on psychiatric diagnosis. Scull, writing in 2015, provides the post-1997 perspective both lacked. He argues that psychotropic drugs’ relative therapeutic impotence paradoxically made them more commercially valuable than cures: chronic, manageable but incurable conditions generate decades of sales, and global antipsychotic sales reached $22 billion by 2010.(Andrew Scull, 2015) The DSM system’s loosening of diagnostic criteria produced a massive expansion of the population defined as mentally ill — juvenile bipolar disorder increased forty-fold between 1994 and 2004, autism diagnosis rose from less than 1 in 500 to 1 in 90 children in a decade, and 10 percent of American boys were taking medication for ADHD.(Andrew Scull, 2015) Whether this expansion reflects improved detection of genuine conditions or the medicalization of normal human variation remains one of the central unsettled questions in contemporary psychiatry.
Scull’s deepest objection to biological reductionism is philosophical rather than epidemiological. Biological psychiatry has proceeded, he argues, by treating the brain as an asocial or pre-social organ, a fixed substrate whose pathologies explain behavior. But the human brain is, in important respects, a product of the social environment: its structure and functioning are shaped by psychosocial and sensory inputs across the lifespan. The metaphysical wager that much of Western medicine embraced centuries ago, that madness had its roots in the body, “has in most respects yet to pay off,” and may never pay off entirely, because the phenomena it seeks to explain are partly constituted by the very environments it has treated as irrelevant.(Andrew Scull, 2015)
Laing’s Existential Critique (1960)
A different line of dissent came not from anthropology but from the phenomenological tradition of European philosophy. R. D. Laing’s The Divided Self (1960) did not engage the second biological psychiatry directly — he was writing before its consolidation — but he attacked the foundational methodological commitment that both biological psychiatry and its psychoanalytic rival shared: the tendency to explain persons in terms of impersonal processes.
Laing’s methodological objection was that the psychiatric vocabulary “consists of words which split man up verbally in a way which is analogous to the existential splits we have to describe.” (Laing, R. D., 1960) Any language system that explained the person through mechanisms, reflexes, or organic processes could not, by its own logic, account for what was specifically personal. “An authentic science of persons,” he argued, had “hardly got started by reason of the inveterate tendency to depersonalize or reify persons.” (Laing, R. D., 1960) Crucially, this was not a rejection of science but a claim about what kind of science psychiatry needed: one that started from the lived experience of the person rather than from observational categories designed for organisms.
The practical consequence was a critique of how clinical knowledge was generated. The standard psychiatric patient, Laing argued, “is a function of the standard psychiatrist, and of the standard mental hospital” — the patient’s behavior is partly shaped by the behavioral field in which it occurs. (Laing, R. D., 1960) The jargon of psychiatry, following van den Berg, he called “a veritable ‘vocabulary of denigration’” that implied a normative standard of being human against which the psychotic was measured and found deficient. (Laing, R. D., 1960) To translate personal understanding into impersonal categories was not to gain knowledge but to lose it: “Depersonalization in a theory that is intended to be a theory of persons is as false as schizoid depersonalization of others and is no less ultimately an intentional act.” (Laing, R. D., 1960)
Laing was explicit that his work made no attempt to “explore constitutional and organic aspects” of schizophrenia and offered no comprehensive biological theory. (Laing, R. D., 1960) By 1965, he had extended his methodological critique into a political one: psychiatry could be “a technique of brainwashing, of inducing behaviour that is adjusted, by (preferably) non-injurious torture.” (Laing, R. D., 1960) This framing, however more radical than his 1960 position, followed from the same starting point: if the standard psychiatric patient is partly a product of the clinical encounter, then clinical power is exercised over persons in a way that the language of disease symptom systematically conceals.
Kleinman’s Anthropological Dissent (1988)
A dissenting perspective came from within psychiatry’s own institutional world. Arthur Kleinman, trained in both psychiatry and anthropology at Harvard, published Rethinking Psychiatry in 1988 as a direct critique of the second biological psychiatry at the moment of its consolidation. He described the era as one of “biological revanchism” — many psychiatrists believed that understanding the biological basis of mental disorders was only two or three streets away, and that such knowledge would make cultural knowledge unnecessary (Arthur Kleinman, 1988). Kleinman’s counter-argument was that psychiatric diagnostic categories were “constrained by history and culture as much as by biology,” because the entire apparatus of psychiatric research — concepts, methodologies, data — was embedded in social systems (Arthur Kleinman, 1988). More pointedly: psychiatric diagnoses are not things in the real world but categories — outcomes of historical development, cultural influence, and political negotiation — that underwrite the interpretation of phenomena which are themselves congeries of psychological, social, and biological processes.(Arthur Kleinman, 1988)
His critique operated on several levels simultaneously. Cross-cultural psychiatry, he noted, maintains a strong systematic bias toward discovering universals and similarities in mental disorder rather than differences, driven by the professional desire to demonstrate that psychiatric disorder is like any other disease detectable everywhere by standardized technique.(Arthur Kleinman, 1988) At the level of epistemology, he argued that the tacit model underlying most cross-cultural psychiatric research — that biology determines the form of mental disease while culture only shapes its content — was a professional orthodoxy inadequate to the evidence (Arthur Kleinman, 1988). The “somatization of mental illness” concept, used to explain why non-Western patients with depression present with bodily complaints rather than psychological distress, exemplified the problem: it treated the Western psychological presentation as the authentic disease form and all other presentations as culturally distorted masks (Arthur Kleinman, 1988). A more accurate model would recognize biological and cultural processes as dialectically interacting, with their relationship often more important than either component alone (Arthur Kleinman, 1988).
At the level of professional sociology, Kleinman identified structural reasons why psychiatry resisted engaging with social sources of mental illness. Despite overwhelming evidence for social contributions to depression onset and course, the thrust of research remained on biological correlates. Biology had “cachet with psychiatrists; anthropology and sociology did not.” Drug companies and psychotherapists derived economic gain from treatment of depression; no commercial interest would benefit from preventive social programs (Arthur Kleinman, 1988). The concept of endogenous depression — depression arising principally from biology rather than environment — had by 1988 already been refuted by researchers who found no episodes arising solely from biological causes, yet even the scientific summaries of this evidence failed to follow their preventive implications (Arthur Kleinman, 1988).
Kleinman also argued that psychiatry had, at the very moment it was moving toward biology, broken with the rest of medicine’s trajectory. Primary care, social medicine, and public health were progressively introducing social science materials; psychiatry was moving in the opposite direction (Arthur Kleinman, 1988). Social science was marginal not because it was irrelevant but because of paradigm incompatibility: the biomedical model treated biology as the infrastructure of disease and psychological and social dimensions as epiphenomenal layers, so that anything described in biological terms was scientifically legitimate while anything described in social-scientific language was suspect (Arthur Kleinman, 1988).
See Also
- asylum
- psychoanalysis
- moral-therapy
- vis-medicatrix-naturae
- pharmacology
- germ-theory
- cellular-pathology
- professionalization
- illness-disease-distinction
Sources
- Shorter, Edward. A History of Psychiatry: From the Era of the Asylum to the Age of Prozac. New York: Wiley, 1997. Evidence cards: sho97-ch01-, sho97-ch04-, sho97-ch07-*.
- Porter, Roy. The Greatest Benefit to Mankind: A Medical History of Humanity. New York: Norton, 1997. Evidence cards: port97-ch16-*.
- Dowbiggin, Ian. Inheriting Madness: Professionalization and Psychiatric Knowledge in Nineteenth-Century France. Berkeley: University of California Press, 1991. (source_id:
dowbiggin-inheritingmadness-1991)